Day One Biopharmaceuticals, Inc.
Clinical trials sponsored by Day One Biopharmaceuticals, Inc., explained in plain language.
Develops targeted therapies for pediatric cancer patients.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug XMT-1660 enters first human tests for Hard-to-Treat cancers Results expected Feb 2027 (estimated)
- New pill may replace chemo for kids with brain tumors Results expected Jun 2027 (estimated) 🚀 Make-or-break
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …
Phase 1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug XMT-1660 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…
Phase 1/2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC